GRI Bio Inc

GRI Bio Inc a clinicalstage biopharmaceutical company focuses on treating inflammatory fibrotic and autoimmune diseases in the United States Its product pipeline comprises GRI0621 which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis GRI0803 which is in phase I trial for the treatment of systematic lupus erythematosus GRI0124 which is in preclinical development for the treatment of primary sclerosing cholangitis and GRI0729 in preclinical development The company also develops ADAIR and ADMIR for treatment of attention deficithyperactivity disorder GRI Bio Inc was formerly known as Glycoregimmune Inc GRI Bio Inc was founded in 2009 and is based in LA Jolla California